Clinical Trial Update: Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA [NA]

View source ↗

Summary

A completed clinical trial evaluated subcutaneous insulin aspart for treating diabetic ketoacidosis. The study also included beta-hydroxybutyrate testing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Ketoacidosis

Drugs mentioned

• NovoLog (insulin aspart)

Snippet

Sponsor: Rush University Medical Center | Conditions: Diabetic Ketoacidosis | NA | Status: COMPLETED